A Phase II Clinical Trial of PXD101 in Patients With Recurrent or Refractory Cutaneous and Peripheral T-Cell Lymphomas.
Latest Information Update: 18 Dec 2023
At a glance
- Drugs Belinostat (Primary)
- Indications Cutaneous T-cell lymphoma; Peripheral T-cell lymphoma
- Focus Therapeutic Use
- Sponsors Valerio Therapeutics
- 01 Apr 2022 This trial has been completed in France, according to European Clinical Trials Database record.
- 26 Oct 2014 Status changed from completed to discontinued as study had accumulated sufficient data to allow a registration study in PTCL (PXD101-CLN-19), as reported by CliniclTrials.gov .
- 01 Sep 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.